# Pep2Tango Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pep2tango-therapeutics

- Industry: Biotechnology
- Headquarters: Potomac, US
- Website: www.pep2tango.com
- Total disclosed funding: $17M
- Latest round: Seed (Sep 20, 2024)
- Investors on record: 1

## About

Based in Maryland, US, and founded in 2021 and led by Chief Executive Officer Cristina Rondinone, Pep2Tango Therapeutics Inc. operates as a biotech research company focused on developing treatments for obesity and related metabolic disorders. In November 2024, Pep2Tango Therapeutics Inc. raised an undisclosed amount of venture funding from Versant Ventures.

Pep2Tango Therapeutics developed new peptide drugs that target unmet medical needs, including metabolic, endocrine, CNS, and cardiovascular disorders. Its drug development approach for obesity focuses on unimolecular peptides that target multiple receptors, allowing for weight loss efficacy, muscle mass preservation, improved tolerability, and streamlined development and manufacturability. As of 2024, the firm’s approach focuses on creating unimolecular tetra-receptor agonist peptides that target four key receptors: GLP-1, GIP, amylin, and calcitonin.

## Funding rounds

- Seed, Sep 20, 2024, $17M — Versant Ventures

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Seed